A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1/2
33
about 2.1 years
18+
Male only
10 sites in CO, CT, FL +6
What this study is about
This trial is testing a treatment called HLD-0915 for men with advanced prostate cancer that has not responded to other treatments. The goal is to see if this treatment is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take HLD-0915
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1: Frequency and severity of AEs and serious adverse events (SAEs), including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs changed from baseline
Secondary: Phase 1: Duration of response (DOR), Phase 1: Objective response rate (ORR) per RECIST in evaluable patients, Phase 1: Plasma PK Parameters (AUC0-inf), Phase 1: Plasma PK Parameters (Cmax), Phase 1: Plasma PK Parameters (T1/2), Phase 1: Plasma PK Parameters (Tmax), Phase 1: Radiographic progression-free survival (rPFS)
Oncology